Questcor's (NASDAQ:QCOR) flagship drug, Acthar, has been around for over 60 years. Despite its age, the company discovered a way to breathe new life into sales of this old drug. So, why does this remain one of the most controversial companies in the health care space today? In this video, Motley Fool health care bureau chief Brenton Flynn takes us through some of his likes and dislikes with Questcor.
Brenton Flynn has no positions in the stocks mentioned above. Max Macaluso has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.